Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease.

Mol Genet Metab Rep · 2025 · PMC12554905 · PMID 41158984

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the change in the rate of eGFR decline before and after initiating SGLT2 therapy did not reach statistical significance, it tended to improve in patients without FD.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.